Opinion

Video

Clinical Considerations for 2L Treatment Sequencing in mCRC

Author(s):

John Marshall, MDAl B. Benson III, MD, FACP, FACCC, FASCO

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

  1. Dr Marshall to Dr Ciombor: What is your current approach for treatment sequencing in the 2L for patients with mCRC that are chemotherapy-refractory?
    • How does prior line of therapy impact your treatment decision-making?

Related Videos
5 KOLs are featured in this program
5 KOLs are featured in this program
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Jonathan C. Trent, MD, PhD
5 KOLs are featured in this panel.
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Related Content
Dr Maximiliano Gelli, Gustave Roussy
June 28th 2024

TRANSMET Regimen Proves Safe, Feasible for Definitively Unresectable CRC Liver Metastasis

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Sara Lonardi, MD
June 28th 2024

Frontline Nivolumab Plus Ipilimumab Reduces Symptomatic Burden in MSI-H/dMMR mCRC

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Gil Efron, chief executive officer, Purple Biotech
June 27th 2024

MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC

Daniel M. Halperin, MD, of The University of Texas MD Anderson Cancer Center
June 27th 2024

Lutetium Lu 177 Dotatate Enters the Pediatric Treatment Paradigm for SSTR+ GEP-NETs